{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T01:41:45Z","timestamp":1755999705533},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1038\/s41390-020-0942-2","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T03:27:24Z","timestamp":1589167644000},"page":"894-899","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Autosomal-dominant polycystic kidney disease: tolvaptan use in adolescents and young adults with rapid progression"],"prefix":"10.1038","volume":"89","author":[{"given":"Rupesh","family":"Raina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronith","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meredith E.","family":"DeCoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Kline","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,11]]},"reference":[{"key":"942_CR1","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1053\/j.ajkd.2015.07.037","volume":"67","author":"FT Chebib","year":"2016","unstructured":"Chebib, F. T. & Torres, V. E. Autosomal dominant polycystic kidney disease: core curriculum 2016. Am. J. Kidney Dis. 67, 792\u2013810 (2016).","journal-title":"Am. J. Kidney Dis."},{"key":"942_CR2","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/nm1004","volume":"10","author":"VE Torres","year":"2004","unstructured":"Torres, V. E. et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat. Med. 10, 363\u2013364 (2004).","journal-title":"Nat. Med."},{"key":"942_CR3","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/j.1523-1755.2004.00843.x","volume":"66","author":"FA Belibi","year":"2004","unstructured":"Belibi, F. A. et al. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int. 66, 964\u2013973 (2004).","journal-title":"Kidney Int."},{"key":"942_CR4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1053\/j.ackd.2011.05.001","volume":"18","author":"KM Dell","year":"2011","unstructured":"Dell, K. M. The spectrum of polycystic kidney disease in children. Adv. Chronic Kidney Dis. 18, 339\u2013347 (2011).","journal-title":"Adv. Chronic Kidney Dis."},{"key":"942_CR5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1053\/j.ajkd.2013.08.017","volume":"63","author":"DC Miskulin","year":"2014","unstructured":"Miskulin, D. C. et al. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study. Am. J. Kidney Dis. 63, 214\u2013226 (2014).","journal-title":"Am. J. Kidney Dis."},{"key":"942_CR6","first-page":"e27","volume":"7","author":"C Blanchette","year":"2015","unstructured":"Blanchette, C. et al. Burden of autosomal dominant polycystic kidney disease: systematic literature review. Am. J. Pharm. Benefits 7, e27\u2013e36 (2015).","journal-title":"Am. J. Pharm. Benefits"},{"key":"942_CR7","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/S0140-6736(15)60907-2","volume":"385","author":"AC Ong","year":"2015","unstructured":"Ong, A. C. et al. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet 385, 1993\u20132002 (2015).","journal-title":"Lancet"},{"key":"942_CR8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2215\/CJN.09500911","volume":"7","author":"AB Chapman","year":"2012","unstructured":"Chapman, A. B. et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 7, 479\u2013486 (2012).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"942_CR9","doi-asserted-by":"crossref","unstructured":"Perrone, R. D. et al. Total kidney volume is a prognostic biomarker of renal function decline and progression to end-stage renal disease in patients with autosomal dominant polycystic kidney disease. Kidney Int. Rep. 2, 442\u2013450 (2017); erratum 3, 1015 (2018).","DOI":"10.1016\/j.ekir.2018.05.006"},{"key":"942_CR10","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.semnephrol.2008.03.003","volume":"28","author":"VE Torres","year":"2008","unstructured":"Torres, V. E. Vasopressin antagonists in polycystic kidney disease. Semin. Nephrol. 28, 306\u2013317 (2008).","journal-title":"Semin. Nephrol."},{"key":"942_CR11","unstructured":"US Food and Drug Administration. Drug approval package: Jynarque (tolvaptan). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/204441Orig1s000TOC.cfm (2018)."},{"key":"942_CR12","unstructured":"Otsuka America Pharmaceutical, Inc. JYNARQUE\u00ae (tolvaptan) Package Insert (Otsuka America Pharmaceutical, Inc., Rockville, MD, 2018)."},{"key":"942_CR13","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres, V. E. et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367, 2407\u20132418 (2012).","journal-title":"N. Engl. J. Med."},{"key":"942_CR14","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres, V. E. et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N. Engl. J. Med. 377, 1930\u20131942 (2017).","journal-title":"N. Engl. J. Med."},{"key":"942_CR15","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1053\/j.ajkd.2010.11.029","volume":"57","author":"VE Torres","year":"2011","unstructured":"Torres, V. E. et al. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) 3\u20134 study. Am. J. Kidney Dis. 57, 692\u2013699 (2011).","journal-title":"Am. J. Kidney Dis."},{"key":"942_CR16","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1097\/01.fjc.0000180899.24865.b6","volume":"46","author":"PJ Hauptman","year":"2005","unstructured":"Hauptman, P. J. et al. Comparison of two doses and dosing regimens of tolvaptan in congestive heart failure. J. Cardiovasc. Pharmacol. 46, 609\u2013614 (2005).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"942_CR17","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1177\/0091270010376193","volume":"51","author":"SE Shoaf","year":"2011","unstructured":"Shoaf, S. E. et al. In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects. J. Clin. Pharmacol. 51, 761\u2013769 (2011).","journal-title":"J. Clin. Pharmacol."},{"key":"942_CR18","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1365-2125.2011.04114.x","volume":"73","author":"SE Shoaf","year":"2012","unstructured":"Shoaf, S. E., Bricmont, P. & Mallikaarjun, S. Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. Br. J. Clin. Pharmacol. 73, 579\u2013587 (2012).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"942_CR19","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1681\/ASN.2015010016","volume":"27","author":"E Cornec-Le Gall","year":"2016","unstructured":"Cornec-Le Gall, E. et al. The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 27, 942\u2013951 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"942_CR20","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/ki.2015.71","volume":"88","author":"H Bhutani","year":"2015","unstructured":"Bhutani, H. et al. A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. Kidney Int. 88, 146\u2013151 (2015).","journal-title":"Kidney Int."},{"key":"942_CR21","unstructured":"US Food and Drug Administration. Qualification of biomarker\u2014total kidney volume in studies for treatment of autosomal dominant polycystic kidney disease. https:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM458483.pdf2015 (2015)."},{"key":"942_CR22","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1681\/ASN.2013101138","volume":"26","author":"MV Irazabal","year":"2015","unstructured":"Irazabal, M. V. et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J. Am. Soc. Nephrol. 26, 160\u2013172 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"942_CR23","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1093\/ndt\/gfs417","volume":"28","author":"I Helal","year":"2013","unstructured":"Helal, I. et al. Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease. Nephrol. Dial. Transplant. 28, 380\u2013385 (2013).","journal-title":"Nephrol. Dial. Transplant."},{"key":"942_CR24","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/1097-0096(200007\/08)28:6<277::AID-JCU2>3.0.CO;2-L","volume":"28","author":"C Nicolau","year":"2002","unstructured":"Nicolau, C. et al. Abdominal sonographic study of autosomal dominant polycystic kidney disease. J. Clin. Ultrasound 28, 277\u2013282 (2002).","journal-title":"J. Clin. Ultrasound"},{"key":"942_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00467-013-2706-2","volume":"30","author":"C Bergmann","year":"2014","unstructured":"Bergmann, C. ARPKD and early manifestations of ADPKD: the original polycystic kidney disease and phenocopies. Pediatr. Nephrol. 30, 15\u201330 (2014).","journal-title":"Pediatr. Nephrol."},{"key":"942_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000491022","volume":"48","author":"R Magistroni","year":"2018","unstructured":"Magistroni, R., Corsi, C., Mart\u00ed, T. & Torra, R. A review of the imaging techniques for measuring kidney and cyst volume in establishing autosomal dominant polycystic kidney disease progression. Am. J. Nephrol. 48, 67\u201378 (2018).","journal-title":"Am. J. Nephrol."},{"key":"942_CR27","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40264-015-0327-3","volume":"38","author":"PB Watkins","year":"2015","unstructured":"Watkins, P. B. et al. Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database. Drug Saf. 38, 1103\u20131113 (2015).","journal-title":"Drug Saf."},{"key":"942_CR28","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1681\/ASN.2016040448","volume":"28","author":"O Devuyst","year":"2017","unstructured":"Devuyst, O. et al. Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3:4 trial. J. Am. Soc. Nephrol. 28, 1592\u20131602 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"942_CR29","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s00431-019-03384-x","volume":"178","author":"F Schaefer","year":"2019","unstructured":"Schaefer, F. et al. Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial. Eur. J. Pediatr. 178, 1013\u20131021 (2019).","journal-title":"Eur. J. Pediatr."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41390-020-0942-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41390-020-0942-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41390-020-0942-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:31:24Z","timestamp":1684618284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-020-0942-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,11]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["942"],"URL":"https:\/\/doi.org\/10.1038\/s41390-020-0942-2","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,11]]},"assertion":[{"value":"17 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed consent was obtained from all patients, and this study was approved by the institutional IRB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}}]}}